{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:32:57Z","timestamp":1790469177645,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1084951"],"award-info":[{"award-number":["1084951"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.060","type":"journal-article","created":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T07:16:07Z","timestamp":1570259767000},"page":"6885-6893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lifetime costs of invasive meningococcal disease: A Markov model approach"],"prefix":"10.1016","volume":"37","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Haji Ali Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2019.09.060_b0005","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.060_b0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.060_b0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/eri.13.42","article-title":"The burden and impact of severe and long-term sequelae of meningococcal disease","volume":"11","author":"Vyse","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.060_b0020","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1524-4733.2008.00327.x","article-title":"Methodological considerations in cost of prostate cancer studies: a systematic review","volume":"11","author":"Molinier","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.060_b0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ip.6.3.177","article-title":"Cost of illness studies: what is good about them?","volume":"6","author":"Rice","year":"2000","journal-title":"Inj Prev"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.060_b0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","article-title":"Cost-of-illness studies: concepts, scopes, and methods","volume":"20","author":"Jo","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.060_b0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/hv.7.4.14434","article-title":"Cost impact of complications in meningococcal disease: evidence from a United States managed care population","volume":"7","author":"Davis","year":"2011","journal-title":"Hum Vaccin"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/hv.7.1.13692","article-title":"Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US","volume":"7","author":"Davis","year":"2011","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.060_b0045","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.ehrm.2011.08.001","article-title":"Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population","volume":"2","author":"Karve","year":"2011","journal-title":"Health Outcomes Res Med"},{"issue":"37","key":"10.1016\/j.vaccine.2019.09.060_b0050","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.09.060_b0055","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","article-title":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","volume":"37","author":"Scholz","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia","volume":"15","author":"Wright","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"39","key":"10.1016\/j.vaccine.2019.09.060_b0065","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.vaccine.2014.07.019","article-title":"Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicaemia","volume":"32","author":"Darba","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.060_b0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","article-title":"Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans","volume":"9","author":"Benard","year":"2016","journal-title":"J Infect Public Health"},{"issue":"29","key":"10.1016\/j.vaccine.2019.09.060_b0075","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.09.060_b0080","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/INF.0000000000001512","article-title":"Cost-effectiveness comparison of monovalent C versus quadrivalent ACWY meningococcal conjugate vaccination in Canada","volume":"36","author":"De Wals","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.060_b0085","doi-asserted-by":"crossref","first-page":"e0175721","DOI":"10.1371\/journal.pone.0175721","article-title":"Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada","volume":"12","author":"Delea","year":"2017","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2019.09.060_b0090","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: a cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.060_b0095","doi-asserted-by":"crossref","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","article-title":"Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands","volume":"8","author":"Hepkema","year":"2013","journal-title":"PLoS ONE"},{"issue":"19","key":"10.1016\/j.vaccine.2019.09.060_b0100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","volume":"34","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.060_b0105","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.060_b0110","doi-asserted-by":"crossref","first-page":"e0123383","DOI":"10.1371\/journal.pone.0123383","article-title":"Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme","volume":"10","author":"Tirani","year":"2015","journal-title":"PLoS ONE"},{"issue":"29","key":"10.1016\/j.vaccine.2019.09.060_b0115","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis","volume":"25","author":"De Wals","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.060_b0120","doi-asserted-by":"crossref","unstructured":"Hanquet GC, Agnew E, Trotter, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. Health Technology Assessment (HTA). 2014;KCE Reports 231.","DOI":"10.57598\/R231C"},{"issue":"23","key":"10.1016\/j.vaccine.2019.09.060_b0125","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2019.09.060_b0130","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2019.09.060_b0135","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40273-018-0693-7","article-title":"Model structuring for economic evaluations of new health technologies","volume":"36","author":"Haji Ali Afzali","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.060_b0140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force\u20132","volume":"15","author":"Roberts","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.060_b0145","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1093\/cid\/cir500","article-title":"Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections","volume":"53","author":"Gottfredsson","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2019.09.060_b0150","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.060_b0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.060_b0160","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Force I-SMGRPT. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2019.09.060_b0165","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.vaccine.2019.09.060_b0170","series-title":"Encyclopedia of health economics","first-page":"340","article-title":"Specification and implementation of decision analytic model structures for economic evaluation of health care technologies","author":"Haji Ali Afzali","year":"2014"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.060_b0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/11590500-000000000-00000","article-title":"A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources","volume":"30","author":"Haji Ali Afzali","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2019.09.060_b0180","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Canberra: Australian Government Department of Health and Ageing; 2016. Available from: https:\/\/pbac.pbs.gov.au\/ [accessed 15 June 2018]."},{"key":"10.1016\/j.vaccine.2019.09.060_b0185","unstructured":"Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) (indicator). Available from: https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm#indicator-chart [accessed 02 July 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.060_b0195","doi-asserted-by":"crossref","first-page":"e9662","DOI":"10.1371\/journal.pone.0009662","article-title":"Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study","volume":"5","author":"Roed","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.060_b0200","series-title":"Textbook of pediatrics","author":"Nelson","year":"2011"},{"issue":"10","key":"10.1016\/j.vaccine.2019.09.060_b0205","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"J Am Acad Child Adolesc Psych"},{"issue":"8","key":"10.1016\/j.vaccine.2019.09.060_b0210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40273-018-0651-4","article-title":"Applying GRADE criteria to clinical inputs to cost-effectiveness modeling studies","volume":"36","author":"Mensch","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"7454","key":"10.1016\/j.vaccine.2019.09.060_b0215","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.vaccine.2019.09.060_b9000","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01241398-198601000-00014","article-title":"Stump overgrowth in juvenile amputees","volume":"6","author":"Abraham","year":"1986","journal-title":"J Pediatr Orthop"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.060_b0225","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BPO.0b013e3182074769","article-title":"Prevalence of stump overgrowth in pediatric burn patient amputations","volume":"31","author":"Klimisch","year":"2011","journal-title":"J Pediatr Orthop"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.060_b0230","first-page":"1","article-title":"Incidence of bone overgrowth in juvenile amputee population","volume":"13","author":"Pellicore","year":"1974","journal-title":"Inter-Clinic Inform Bull"},{"key":"10.1016\/j.vaccine.2019.09.060_b0235","unstructured":"Tooms RE. Acquired amputations in children. In: Bowker JH, Michael JW, editors. American Academy of Orthopaedic Surgeons. Atlas of limb prosthetics: surgical, prosthetic, and rehabilitation principles. 2nd ed. Mosby Inc; 1992."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.09.060_b0240","doi-asserted-by":"crossref","first-page":"i89","DOI":"10.1136\/ard.2009.117150","article-title":"The value of productivity: human-capital versus friction-cost method","volume":"69","author":"van den Hout","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10198-014-0652-y","article-title":"Estimating productivity costs using the friction cost approach in practice: a systematic review","volume":"17","author":"Kigozi","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.060_b0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","article-title":"The friction cost method for measuring indirect costs of disease","volume":"14","author":"Koopmanschap","year":"1995","journal-title":"J Health Econ"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.060_b0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.060_b0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.bpo.0000187991.71645.e7","article-title":"Orthopaedic sequelae of meningococcal septicemia","volume":"26","author":"Bache","year":"2006","journal-title":"J Pediatr Orthop"},{"issue":"8","key":"10.1016\/j.vaccine.2019.09.060_b0265","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/civ028","article-title":"Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study","volume":"60","author":"Sadarangani","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:31Z","timestamp":1759401271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":54,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312848"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifetime costs of invasive meningococcal disease: A Markov model approach","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}